Literature DB >> 26603836

Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas.

Biljana Culjkovic-Kraljacic1, Tharu M Fernando2, Rossella Marullo2, Nieves Calvo-Vidal2, Akanksha Verma3, ShaoNing Yang2, Fabrizio Tabbò4, Marcello Gaudiano5, Hiba Zahreddine1, Rebecca L Goldstein2, Jayeshkumar Patel2, Tony Taldone6, Gabriela Chiosis6, Marco Ladetto7, Paola Ghione8, Rodolfo Machiorlatti9, Olivier Elemento3, Giorgio Inghirami5, Ari Melnick2, Katherine L B Borden1, Leandro Cerchietti2.   

Abstract

Aggressive double- and triple-hit (DH/TH) diffuse large B-cell lymphomas (DLBCLs) feature activation of Hsp90 stress pathways. Herein, we show that Hsp90 controls posttranscriptional dynamics of key messenger RNA (mRNA) species including those encoding BCL6, MYC, and BCL2. Using a proteomics approach, we found that Hsp90 binds to and maintains activity of eIF4E. eIF4E drives nuclear export and translation of BCL6, MYC, and BCL2 mRNA. eIF4E RNA-immunoprecipitation sequencing in DLBCL suggests that nuclear eIF4E controls an extended program that includes B-cell receptor signaling, cellular metabolism, and epigenetic regulation. Accordingly, eIF4E was required for survival of DLBCL including the most aggressive subtypes, DH/TH lymphomas. Indeed, eIF4E inhibition induces tumor regression in cell line and patient-derived tumorgrafts of TH-DLBCL, even in the presence of elevated Hsp90 activity. Targeting Hsp90 is typically limited by counterregulatory elevation of Hsp70B, which induces resistance to Hsp90 inhibitors. Surprisingly, we identify Hsp70 mRNA as an eIF4E target. In this way, eIF4E inhibition can overcome drug resistance to Hsp90 inhibitors. Accordingly, rational combinatorial inhibition of eIF4E and Hsp90 inhibitors resulted in cooperative antilymphoma activity in DH/TH DLBCL in vitro and in vivo.
© 2016 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26603836      PMCID: PMC4760090          DOI: 10.1182/blood-2015-05-645069

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  29 in total

Review 1.  The role of heat shock proteins in cancer.

Authors:  Georgios D Lianos; George A Alexiou; Alberto Mangano; Alessandro Mangano; Stefano Rausei; Luigi Boni; Gianlorenzo Dionigi; Dimitrios H Roukos
Journal:  Cancer Lett       Date:  2015-02-23       Impact factor: 8.679

2.  BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy.

Authors:  Leandro C Cerchietti; Katerina Hatzi; Eloisi Caldas-Lopes; Shao Ning Yang; Maria E Figueroa; Ryan D Morin; Martin Hirst; Lourdes Mendez; Rita Shaknovich; Philip A Cole; Kapil Bhalla; Randy D Gascoyne; Marco Marra; Gabriela Chiosis; Ari Melnick
Journal:  J Clin Invest       Date:  2010-11-01       Impact factor: 14.808

3.  A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E.

Authors:  Sarit Assouline; Biljana Culjkovic-Kraljacic; Julie Bergeron; Stephen Caplan; Eftihia Cocolakis; Caroline Lambert; Cara J Lau; Hiba Ahmad Zahreddine; Wilson H Miller; Katherine L B Borden
Journal:  Haematologica       Date:  2014-11-25       Impact factor: 9.941

Review 4.  Selective targeting of the stress chaperome as a therapeutic strategy.

Authors:  Tony Taldone; Stefan O Ochiana; Pallav D Patel; Gabriela Chiosis
Journal:  Trends Pharmacol Sci       Date:  2014-09-25       Impact factor: 14.819

5.  Differential Requirements for eIF4E Dose in Normal Development and Cancer.

Authors:  Morgan L Truitt; Crystal S Conn; Zhen Shi; Xiaming Pang; Taku Tokuyasu; Alison M Coady; Youngho Seo; Maria Barna; Davide Ruggero
Journal:  Cell       Date:  2015-06-18       Impact factor: 41.582

Review 6.  The eukaryotic translation initiation factor eIF4E in the nucleus: taking the road less traveled.

Authors:  Michael J Osborne; Katherine L B Borden
Journal:  Immunol Rev       Date:  2015-01       Impact factor: 12.988

7.  Genetic and pharmacologic inhibition of eIF4E reduces breast cancer cell migration, invasion, and metastasis.

Authors:  Filippa Pettersson; Sonia V Del Rincon; Audrey Emond; Bonnie Huor; Elaine Ngan; Jonathan Ng; Monica C Dobocan; Peter M Siegel; Wilson H Miller
Journal:  Cancer Res       Date:  2015-01-21       Impact factor: 12.701

8.  Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma.

Authors:  Rebecca L Goldstein; Shao Ning Yang; Tony Taldone; Betty Chang; John Gerecitano; Kojo Elenitoba-Johnson; Rita Shaknovich; Wayne Tam; John P Leonard; Gabriela Chiosis; Leandro Cerchietti; Ari Melnick
Journal:  J Clin Invest       Date:  2015-11-03       Impact factor: 14.808

9.  Proteomic analysis of cap-dependent translation identifies LARP1 as a key regulator of 5'TOP mRNA translation.

Authors:  Joseph Tcherkezian; Marie Cargnello; Yves Romeo; Edward L Huttlin; Genevieve Lavoie; Steven P Gygi; Philippe P Roux
Journal:  Genes Dev       Date:  2014-02-15       Impact factor: 11.361

10.  The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation.

Authors:  Hiba Ahmad Zahreddine; Biljana Culjkovic-Kraljacic; Sarit Assouline; Patrick Gendron; Andrea A Romeo; Stephen J Morris; Gregory Cormack; James B Jaquith; Leandro Cerchietti; Eftihia Cocolakis; Abdellatif Amri; Julie Bergeron; Brian Leber; Michael W Becker; Shanshan Pei; Craig T Jordan; Wilson H Miller; Katherine L B Borden
Journal:  Nature       Date:  2014-05-28       Impact factor: 49.962

View more
  37 in total

Review 1.  A Chemical Biology Approach to the Chaperome in Cancer-HSP90 and Beyond.

Authors:  Tony Taldone; Tai Wang; Anna Rodina; Naga Vara Kishore Pillarsetty; Chander S Digwal; Sahil Sharma; Pengrong Yan; Suhasini Joshi; Piyusha P Pagare; Alexander Bolaender; Gail J Roboz; Monica L Guzman; Gabriela Chiosis
Journal:  Cold Spring Harb Perspect Biol       Date:  2020-04-01       Impact factor: 10.005

Review 2.  Adapting to stress - chaperome networks in cancer.

Authors:  Suhasini Joshi; Tai Wang; Thaís L S Araujo; Sahil Sharma; Jeffrey L Brodsky; Gabriela Chiosis
Journal:  Nat Rev Cancer       Date:  2018-09       Impact factor: 60.716

3.  Therapeutic implication of concomitant chromosomal aberrations in patients with aggressive B-cell lymphomas.

Authors:  Rossella Marullo; Sarah C Rutherford; John P Leonard; Leandro Cerchietti
Journal:  Cell Cycle       Date:  2016-07-15       Impact factor: 4.534

4.  The oncogenic membrane protein LMP1 sequesters TRAF3 in B-cell lymphoma cells to produce functional TRAF3 deficiency.

Authors:  Pradeep Bangalore-Prakash; Laura L Stunz; Nurbek Mambetsariev; Amy L Whillock; Bruce S Hostager; Gail A Bishop
Journal:  Blood Adv       Date:  2017-12-18

5.  Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma.

Authors:  Colleen T Harrington; Elena Sotillo; Aude Robert; Katharina E Hayer; Agata M Bogusz; James Psathas; Duonan Yu; Deanne Taylor; Chi V Dang; Peter S Klein; Michael D Hogarty; Birgit Geoerger; Wafik S El-Deiry; Joëlle Wiels; Andrei Thomas-Tikhonenko
Journal:  Leukemia       Date:  2019-03-26       Impact factor: 11.528

Review 6.  Proteomic interrogation of HSP90 and insights for medical research.

Authors:  Lorenz Weidenauer; Tai Wang; Suhasini Joshi; Gabriela Chiosis; Manfredo R Quadroni
Journal:  Expert Rev Proteomics       Date:  2017-10-16       Impact factor: 3.940

7.  Venetoclax response is enhanced by selective inhibitor of nuclear export compounds in hematologic malignancies.

Authors:  Melissa A Fischer; Sharon Y Friedlander; Maria P Arrate; Hua Chang; Agnieszka E Gorska; Londa D Fuller; Haley E Ramsey; Trinayan Kashyap; Christian Argueta; Sophie Debler; Michael Byrne; Matthew T Villaume; Aaron C Shaver; William Senapedis; Yosef Landesman; Erkan Baloglu; Sharon Shacham; Michael R Savona
Journal:  Blood Adv       Date:  2020-02-11

8.  Importin 8 mediates m7G cap-sensitive nuclear import of the eukaryotic translation initiation factor eIF4E.

Authors:  Laurent Volpon; Biljana Culjkovic-Kraljacic; Michael J Osborne; Anup Ramteke; Qingxiang Sun; Ashley Niesman; Yuh Min Chook; Katherine L B Borden
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-25       Impact factor: 11.205

9.  Structural studies of the eIF4E-VPg complex reveal a direct competition for capped RNA: Implications for translation.

Authors:  Luciana Coutinho de Oliveira; Laurent Volpon; Amanda K Rahardjo; Michael J Osborne; Biljana Culjkovic-Kraljacic; Christian Trahan; Marlene Oeffinger; Benjamin H Kwok; Katherine L B Borden
Journal:  Proc Natl Acad Sci U S A       Date:  2019-11-11       Impact factor: 11.205

Review 10.  RNA-binding proteins in hematopoiesis and hematological malignancy.

Authors:  Daniel J Hodson; Michael Screen; Martin Turner
Journal:  Blood       Date:  2019-04-09       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.